Foslevodopa
Vyalev (foslevodopa) is a small molecule pharmaceutical. Foslevodopa was first approved as Vyalev on 2024-10-16.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Vyalev
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vyalev | New Drug Application | 2024-10-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Foslevodopa |
| INN | foslevodopa |
| Description | Foslevodopa is an L-tyrosine derivative that is L-dopa in which the hydroxy group at position 4' is replaced by a phosphonooxy group. It is a water-soluble prodrug of levodopa which is used for the treatment of Parkinson's disease. It has a role as an antiparkinson drug and a prodrug. It is a L-tyrosine derivative, a non-proteinogenic L-alpha-amino acid and an O-phosphoamino acid. It is functionally related to a L-dopa. |
| Classification | Small molecule |
| Drug class | dopamine receptor agonists; phosphoro-derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 97321-87-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594379 |
| ChEBI ID | — |
| PubChem CID | 127766 |
| DrugBank | DB16683 |
| UNII ID | 37NQZ0J76I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use